Skip to main content

Loss of Pregnancy in a Patient with Chronic Myeloid Leukemia During Treatment with Nilotinib

Audiocasts - Original Research

Justin Arnall, PharmD, discusses the clinical significance of his research and case study on, “Loss of Pregnancy in a Patient with Chronic Myeloid Leukemia During Treatment with Nilotinib.”

Related Items
Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study
JHOP - June 2026 Vol 16, No 3 published on February 25, 2026 in Original Research, Checkpoint Inhibitors, Adverse Events, Lung Cancer
Management Patterns and Perceived Educational Needs Related to Cancer Therapy Cardiovascular Toxicities for Cardio-Oncology Providers
JHOP - June 2026 Vol 16, No 3 published on February 19, 2026 in Original Research, Adverse Events, Drug–Drug Interaction
Risk for Vincristine-Induced Adverse Events With Aprepitant in Pediatric Patients With Rhabdomyosarcoma
JHOP - April 2026 Vol 16, No 2 published on January 20, 2026 in Original Research, Adverse Events, Chemotherapy, Drug–Drug Interaction
Infusion-Related Reactions Associated With Nivolumab and Pembrolizumab: A Case Series Analysis
JHOP - June 2026 Vol 16, No 3 published on January 8, 2026 in Original Research, Checkpoint Inhibitors, Infusion Issues, PD-1 Inhibitors
Impact of Universal Pegaspargase Premedication on Substitution Rates and Adverse Events
JHOP - August 2026 Vol 16, No 4 published on January 8, 2026 in Original Research, Adverse Events, Pediatric Cancer, Acute Lymphoblastic Leukemia
Evaluation of Initial Weight-Based Tacrolimus Dosing After Allogeneic Hematopoietic Stem Cell Transplant
JHOP - April 2026 Vol 16, No 2 published on January 7, 2026 in Original Research, Adverse Events, Transplant
Letermovir Prophylaxis After Stem Cell Transplant in Pediatric Patients Aged Younger than 12 Years
JHOP - April 2026 Vol 16, No 2 published on January 2, 2026 in Original Research, Pediatric Cancer, Transplant
Analysis of Ifosfamide-Associated Encephalopathy Between 2 Formulations in Adults With Hematologic Cancer
JHOP - December 2025 Vol 15, No 6 published on December 1, 2025 in Original Research, Adverse Events
A Survey of Biosimilar Adoption Across Oncology Pharmacy Practices
JHOP - December 2025 Vol 15, No 6 published on December 1, 2025 in Original Research, Biosimilars
Evaluation of Serious Immune-Related Adverse Event Incidence in 200-mg Versus 400-mg Pembrolizumab Regimens
JHOP - December 2025 Vol 15, No 6 published on December 1, 2025 in Original Research, Adverse Events, Immunotherapy